Dr. Susan M. Faust, CEO and InventorGene therapy aims to replace or supplement faulty or missing genes responsible for serious, often life-threatening disorders. AAV vectors act as delivery vehicles, transporting healthy DNA into target tissues so the body can produce the proteins it needs.
But for decades, a single biological barrier has stood in the way: the innate immune system. The body can mistake therapeutic AAV vectors, which act as delivery vehicles carrying precious genetic cargo, for viral invaders, triggering the Toll-like receptor 9 (TLR9) pathway. This sets off inflammatory cascades that compromise patient safety, curtail gene expression, limit efficacy, and prevent repeat dosing.
NxGEN’s breakthrough came by pinpointing and removing the precise genetic signal—unmethylated CpG motifs—that ignite this immune response. By redesigning the AAV genome to eliminate these motifs, NxGEN created a new class of CpG-depleted vectors that avoid immune recognition, maintain transgene expression, and deliver therapeutic benefit safely.
This discovery redefined the principles of durability and safety in gene therapy. NxGEN Vector Solutions’ platform now directly addresses the three greatest challenges faced by developers today: overcoming immune activation to prevent inflammatory responses; sustaining long-term gene expression for lasting benefit; and reducing clinical risk to improve success rates.
By enabling AAV vectors to “fly under the immune radar,” NxGEN Vector Solutions has ushered in a new era of durable, repeatable, and safe genetic medicines— fulfilling the promise that gene therapy has long pursued.
“NxGEN Vector Solutions has built a breakthrough that reframes how the entire field thinks about durability and safety in gene therapy. The rare ability to solve the most persistent challenges, such as immune rejection of AAV-based gene therapies, is what defines NxGEN,” says Dr. Susan M. Faust, CEO and inventor.
Validated by Science
The principles behind CpG depletion were first explored in early studies from 2012 and 2013, led by Dr. Faust, whose foundational work revealed how reducing CpG motifs from AAV vector genomes could suppress immune activation and enable long-term transgene expression in muscle and liver gene-transfer models. Those early studies laid down the groundwork and resulted in the invention of NxGEN’s CpG-depletion technology, which has since become an industry standard. Today, NxGEN Vector Solutions’ proprietary platform builds upon that legacy—protected by strong intellectual property and recognized across FDA advisories, peer-reviewed publications, and technical white papers issued by leading pharmaceutical organizations.
The impact of CpG depletion has been validated across both preclinical models and human clinical trials. In animal studies, CpG-reduced vectors consistently evaded immune detection and sustained high levels of gene expression with minimal inflammatory complications, findings that were translated directly into the clinic. A pivotal 2020 analysis of hemophilia B trials in humans further reinforced this effect: CpG content was identified as the only consistent determinant of durable therapeutic success. Patients treated with CpG-depleted vectors achieved stable, long-term expression, whereas those receiving CpG-rich constructs did not.
-
NxGEN Vector Solutions has built a breakthrough that reframes how the entire field thinks about durability and safety in gene therapy. The rare ability to solve the most persistent challenges, such as immune rejection of AAV-based gene therapies, is what defines NxGEN.
The principles behind CpG depletion were first explored in early studies from 2012 and 2013, led by Dr. Faust, whose foundational work revealed how reducing CpG motifs from AAV vector genomes could suppress immune activation and enable long-term transgene expression in muscle and liver gene-transfer models. Those early studies laid down the groundwork and resulted in the invention of NxGEN’s CpG-depletion technology, which has since become an industry standard. Today, NxGEN Vector Solutions’ proprietary platform builds upon that legacy—protected by strong intellectual property and recognized across FDA advisories, peer-reviewed publications, and technical white papers issued by leading pharmaceutical organizations.
Additionally, NxGEN Vector Solutions has developed its proprietary PD-L1 cardiac gene therapy, designed to locally upregulate PD-L1 expression in transplanted heart tissue and create a targeted, durable, immune-tolerant environment that protects the graft without requiring systemic immunosuppression. By pairing PD-L1 modulation with CpG-depleted AAV vectors, this approach aims to prevent chronic rejection and preserve long-term cardiac function. This demonstrates to clients that NxGEN Vector Solutions practices what it preaches: it is CpG-depleting its own gene-therapy programs.
Transforming Delivery into Durability
The promise of gene therapy lies in its durability. Patients and developers seek solutions that last. By addressing the immune reaction at its source, NxGEN helps companies reduce risk and improve the likelihood of success. Its vectors operate with stealth, staying below the immune radar while delivering their genetic payload effectively and safely.
For NxGEN’s partners, this translates into de-risked development programs, durable results, and ultimately safer gene therapies for patients. NxGEN works closely with clients who license its technology and gain access to its scientific consulting. The company assists them in applying CpG-depletion strategies to their own gene-therapy programs to enhance safety and transgene expression from the start.
NxGEN’s work is transforming the development and delivery of gene therapy. What began as a scientific observation about immune-system behavior has evolved into a cornerstone technology for building genetic medicine. Through every partnership and program, the company is advancing the field toward safer, long-lasting, and more reliable therapies that deliver on the full potential of science.
An Open Letter to the Gene Therapy Community on CpG Content and AAV Vector Safety
Susan M. Faust, PhD Founder
At NxGEN Vector Solutions, we are advancing next-generation AAV vector design with a focus on genomic optimization, safety, and durable therapeutic expression. Our work centers on reducing immunogenic elements such as CpG motifs across the entire vector genome, enabling more predictable, long-lasting outcomes for patients while supporting the continued evolution of gene therapy toward safer and more effective treatments.
Deep Dive
Gene Therapy Solutions That Can Hold Up Under Clinical Pressure
Gene therapy has entered a very different phase of maturity. What once lived mostly in research discussions now sits squarely inside boardroom conversations about durability, safety, regulatory scrutiny and commercial viability. Biotechnology leaders are no longer evaluating vendors for a narrow technical capability alone. They are making decisions that can influence whether a therapy continues to express years after treatment effectively or runs into safety and immune-response issues that weaken the entire development program.
That pressure is especially visible in AAV-based gene therapies. Delivering therapeutic genetic material into target cells is only part of the challenge. The vector also has to avoid triggering immune responses that can reduce expression, limit dosing flexibility or introduce safety concerns that complicate clinical progress. What looks promising in preclinical development can become much harder to manage once human biology enters the equation.
To a management team, it changes vector design from a scientific endeavor into a more complex risk management decision. Vector engineering, the design of the payload, immune recognition and lasting expression are all very interconnected, and what causes a problem in one area is sure to have an effect in another area later on. A treatment that loses expression due to an immune response may not get future funding despite positive early efficacy. Toxicity concerns can create the same issue by narrowing dose options or raising questions about long-term tolerability.
The financial implications make it that much more difficult to walk away from in retrospect. A gene therapy program takes years of development and money before the sponsor will be clear whether their initial vector hypotheses will be validated in the clinic. Post-clinical entry, immune-mediated loss of expression and potentially detrimental inflammatory responses could severely compromise an entire program. Sponsors desire collaborators who can spot those potential risks and develop scientifically sound means to circumvent them before they represent major clinical costs.
Strong gene therapy solution providers are usually differentiated by how clearly they explain the biology behind their approach. Broad claims around delivery efficiency are no longer enough. Biotechnology companies want evidence showing why therapeutic expression is likely to persist, how immune activation may be reduced and whether the underlying scientific rationale has been tested and recognized across the wider research community. Publication history, peer engagement and clinical interpretation all matter because they help sponsors assess whether a platform has credibility beyond isolated laboratory data.
Practical integration matters too. Development teams need intellectual property access, construction design support and scientific consultation that fit into existing workflows without introducing unnecessary complexity. The most valuable partners are often the ones that help sponsors make clearer vector decisions and build stronger development plans rather than simply offering another technical feature.
NxGEN Vector Solutions has focused its work on one of the central challenges in AAV gene therapy: immune recognition at the vector-genome level. Its CpG-depletion approach is designed to reduce activation of TLR9, with the goal of supporting safer and more durable therapeutic gene expression. The company licenses its patented gene therapy technology to strategic partners while also providing construct design and consulting support for CpG-depleted AAV vectors. For biotechnology executives weighing long-term expression durability against immune-related development risk, the company’s approach addresses a problem that has become increasingly difficult for the industry to ignore.
...Read more
Gene Therapy Solution Info
Q1
What distinguishes NxGEN Vector Solutions among Top Gene Therapy Solutions providers?
NxGEN Vector Solutions has earned recognition among Top Gene Therapy Solutions providers through its patented CpG-depletion technology designed to address one of gene therapy’s most persistent challenges: immune system activation. The company focuses on optimizing adeno-associated virus (AAV) vector genomes to reduce inflammatory immune responses that can compromise therapeutic durability and patient safety. Its scientific platform enables vectors to avoid triggering Toll-like receptor 9 (TLR9) immune pathways, improving long-term gene expression and reducing clinical risk. NxGEN Vector Solutions also differentiates itself through its deep specialization in genome optimization rather than relying solely on capsid engineering strategies.
Q2
How does NxGEN Vector Solutions approach gene therapy development?
Immune-system precision forms the foundation of the company’s development strategy. Unlike many Gene Therapy Solutions providers that focus primarily on delivery mechanisms, NxGEN Vector Solutions targets the genetic elements within AAV vectors that activate immune responses. By removing unmethylated CpG motifs from vector genomes, the company creates CpG-depleted vectors capable of sustaining therapeutic gene expression with reduced inflammatory complications. Its platform supports safer and more durable gene transfer across multiple therapeutic applications while helping developers improve clinical reliability from the earliest development stages.
Q3
Why is NxGEN Vector Solutions relevant to the future of gene therapy?
Long-term durability and immune tolerance remain central challenges across the gene therapy sector, particularly in AAV-based therapeutic development. NxGEN Vector Solutions addresses these industry concerns through Gene Therapy Solutions designed to reduce immune detection and improve sustained therapeutic benefit. Its technology has gained attention across preclinical and clinical research because CpG content has been identified as a major determinant of long-term transgene expression success. The company’s work also supports broader healthcare efforts to improve repeat dosing potential and reduce safety risks associated with immune-mediated treatment limitations.
Q4
What role does scientific innovation play at NxGEN Vector Solutions?
Research-driven innovation remains central to NxGEN Vector Solutions’ scientific identity. The company’s foundational discoveries originated from early studies led by Dr. Susan M. Faust that demonstrated how reducing CpG motifs in AAV vectors could suppress immune activation and improve therapeutic persistence. Its proprietary platform has since evolved into a widely recognized genome optimization approach referenced in FDA advisories, scientific publications and industry white papers. Gene Therapy Solutions providers often differentiate themselves through platform originality and clinical relevance, and NxGEN reinforces that distinction through its focus on durability, immune stealth and vector safety engineering.
Q5
How does NxGEN Vector Solutions support gene therapy developers and partners?
Collaborative scientific support plays an important role in the company’s business model. NxGEN Vector Solutions works closely with biotechnology and pharmaceutical partners that license its technology and apply CpG-depletion strategies within their own therapeutic programs. The company provides scientific consulting, vector optimization guidance and development support designed to improve safety profiles and long-term transgene expression. Among Gene Therapy Solutions providers, NxGEN distinguishes itself through its ability to combine proprietary vector engineering with practical translational support tailored to partner-specific therapeutic goals.
Q6
Why has NxGEN Vector Solutions gained industry recognition in gene therapy?
Industry recognition for NxGEN Vector Solutions reflects its contributions to solving immune-related barriers that have historically limited gene therapy effectiveness. Life Sciences Review recognized the company as a Top Gene Therapy Solution provider for its breakthrough CpG-depletion platform and its impact on improving AAV vector durability and safety. Its technology has demonstrated relevance across both animal studies and human clinical trial analyses involving long-term therapeutic expression. This combination of scientific innovation, immune-system expertise and practical vector optimization continues to strengthen NxGEN Vector Solutions’ standing within Gene Therapy Solutions.
